Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$16.88
-0.41%
-0.41%
410K
|
Health Technology
(0.0% 1d) (-14.0% 1m) (43.4% 1y) (0.0% 2d) (-2.9% 3d) (-2.0% 7d) (27.66% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 674,867,160
http://www.kiniksa.com
Sec Filling | Patents | 137 employees
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
add to watch list Paper trade email alert is off
Press-releases
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.09%
H: 0.86%
C: -0.3%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.46%
H: 0.17%
C: -3.36%
first report pharmaceuticals financial results
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.05%
H: 0.02%
C: -2.62%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 0.06%
H: 0.22%
C: 0.0%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.23%
H: 1.58%
C: 0.06%
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -0.55%
H: 1.39%
C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 0.0%
H: 0.39%
C: -0.66%
positive growth market
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -4.0%
pharmaceuticals
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Published: 2024-02-28 (Crawled : 12:30) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.17%
H: 0.33%
C: -0.74%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 4.93%
H: 0.27%
C: -7.12%
pharmaceuticals financial results
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Published: 2024-02-21 (Crawled : 21:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.08%
H: 2.04%
C: 1.19%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.2%
H: 0.25%
C: -1.4%
report pharmaceuticals financial results
Kiniksa Pharmaceuticals Provides Corporate Update
Published: 2024-01-04 (Crawled : 12:30) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.02%
H: 0.77%
C: -0.61%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: -4.14%
update pharmaceuticals
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 21:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.2%
H: 1.85%
C: 1.19%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: -0.54%
H: 10.47%
C: 8.41%
conference pharmaceuticals
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.33%
H: 0.92%
C: 0.61%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: -4.97%
H: 12.89%
C: 2.35%
pharmaceuticals financial results
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
Published: 2023-10-24 (Crawled : 20:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.37%
H: 0.14%
C: -0.53%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: -1.17%
H: 2.05%
C: 0.13%
report pharmaceuticals financial results
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
Published: 2023-07-25 (Crawled : 12:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.54%
H: 1.31%
C: 0.92%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 12.72%
H: 18.76%
C: 15.68%
pharmaceuticals financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10